🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

659 results for “MS” Clear

  1. A Phase 1 Study of BMS-986406 as Monotherapy and in Combination in Advanced Tumors

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced Malignant Tumors

    phase 1 other active

    1 trial

  2. A Phase 1 Study of BMS-986453 in Participants with Relapsed and/or Refractory Multiple Myeloma

    Celgene Europe Limited

    Relapsed and/or Refractory Multiple Myeloma

    phase 1 other active

    1 trial

  3. A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced or metastatic solid tumors, Gastroesophageal cancer (GEC), High grade serous ovarian cancer (HGSOC), Endometrial cancer (EC), Advanced or metastatic breast cancer, Platinum-resistant ovarian cancer (PROC)

    phase 1 other active

    1 trial

  4. A Phase 1 Study of CD19-targeted NEX-T CAR T Cells in Participants with RMS, PMS, or MG(Breakfree-2)

    Celgene Europe Limited

    Myasthenia gravis (MG), Progressive Multiple Sclerosis (PMS), Relapsing Multiple Sclerosis (RMS)

    phase 1 other active

    1 trial

  5. A Phase 1 Study of JNJ-88549968, a T-cell Redirecting Antibody, for CALR-mutated Myeloproliferative Neoplasms

    Janssen-Cilag International N.V.

    CALR-mutated Myeloproliferative Neoplasms

    phase 1 other active

    1 trial

  6. A Phase 1 Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms

    Janssen-Cilag International N.V.

    Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Types of Myelodysplastic Neoplasms

    phase 1 other active

    1 trial

  7. A Phase 1 study of GSK5764227 in participants with advanced solid tumors

    GlaxoSmithKline

    Neoplasms

    phase 1 other active

    1 trial

  8. A Phase 1, First-in-Human, Dose Escalation Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms

    Janssen-Cilag International N.V.

    Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Types of Myelodysplastic Neoplasms

    phase 1 other active

    1 trial

  9. A Phase 1, Open-Label, Multicenter Study of INCB160058 in Participants With Myeloproliferative Neoplasms.

    Incyte

    Myeloproliferative Neoplasms

    phase 1 other active

    1 trial

  10. A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

    Incyte

    Treatment of participants with MF, MDS, ET, or MDS/MPN

    phase 1 other active

    1 trial

  11. A Phase 1, open label, randomized, 2-sequence, 2-period, crossover, single center study to evaluate the pharmacokinetics of follitropin alfa from 2 manufacturing processes, administered as a single subcutaneous 450 IU dose to pituitary-suppressed healthy premenopausal female participants.

    Merck Sharp and Dohme

    Infertility

    phase 1 other active

    1 trial

  12. A Phase 1/1b First-in-Human Study of BMS-986506 in ccRCC

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced Clear Cell Renal Cell Carcinoma

    phase 1 other active

    1 trial

  13. A Phase I First Time in Human Open Label Study of GSK3745417 Administered With and Without Anticancer Agents in Participants With Advanced Solid Tumors

    GlaxoSmithKline

    Neoplasms

    phase 1 other active

    1 trial

  14. A Phase I Study of BMS-986497 alone or in combination with Azacitidine (Aza) and Azacitidine plus Venetoclax (AZA+VEN) in relapsed or refractory (R/R) AML or MDS

    Bristol-Myers Squibb Australia Pty Ltd

    Acute Myeloid Leukemia and Myelodysplastic Syndrome

    phase 1 other active

    1 trial

  15. A Phase I study to evaluate the safety and efficacy of L19IL2 in combination with ruxolitinib in patients with advanced solid tumors.

    Philogen S.p.A.

    Advanced solid tumors, specifically: • metastatic clear cell renal carcinoma • proficient mismatch repair / microsatellite stable (pMMR/MSS), BRAF-V600E-mutant negative colorectal carcinoma • locally advanced or metastatic pancreatic adenocarcinoma

    phase 1 other active

    1 trial

  16. A Phase I, Open-label, Multi-center, First-in-human Trial to Investigate E303, in Participants with Advanced Refractory Solid Tumors

    Samsung Bioepis NL B.V.

    advanced refractory solid tumors

    phase 1 other active

    1 trial

  17. A SINGLE-ARM, OPEN-LABEL, PHASE I STUDY TO DETERMINE THE SAFETY, TOLERABILITY, AND PRELIMINARY EFFICACY OF OBE-CEL IN PARTICIPANTS WITH REFRACTORY PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS

    Autolus GmbH

    Refractory Progressive Multiple Sclerosis

    phase 1 other active

    1 trial

  18. A Study of LY4257496 in Participants With Cancer (OMNIRAY)

    Eli Lilly Co.

    Breast Neoplasms Colorectal Neoplasms Prostate Neoplasm Endometrial Neoplasms Neoplasm Metastasis

    phase 1 other active

    1 trial

  19. A Study to Investigate Relative Bioavailability of Two Different Dosage Forms for Tozorakimab via Subcutaneous Administration in Healthy Volunteers

    AstraZeneca AB

    healthy volunteers

    phase 1 other active

    1 trial

  20. A Study to Investigate Single Ascending Doses of Ocrelizumab for Safety and Side Effects, How The Body Handles It Over A Period of Time, How The Body Notices and Reacts To It, And Its Effect On The Body When Given As A Subcutaneous Injection In Patients With Multiple Sclerosis

    Hoffmann-La Roche

    Multiple Sclerosis (MS)

    phase 1 other active

    1 trial

  21. A Study to Investigate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of Ascending Intravenous Doses of Glofitamab, Administered after Ocrelizumab Pretreatment, in Patients with Multiple Sclerosis

    Hoffmann-La Roche

    Multiple Sclerosis (MS)

    phase 1 other active

    1 trial

  22. A Study to Investigate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of RO7121932 following Intravenous and Subcutaneous Administration in Participants with Multiple Sclerosis

    Hoffmann-La Roche

    Multiple Sclerosis (MS)

    phase 1 other active

    1 trial

  23. A Study to Learn How Different Forms of The Study Medicine Called Prazosin Are Taken up Into the Blood in Healthy Adults

    Pfizer Australia Pty Ltd

    Primary and secondary hypertension, and heart failure

    phase 1 other active

    1 trial

  24. A TQT Study to Investigate the Effect of Enpatoran on Cardiac Repolarization in Healthy Participants

    Merck Sharp and Dohme

    Healthy

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources